China gives emergency use approval to first mRNA vaccine against Covid-19
[ad_1]
The first Covid-19 vaccine in China, containing a messenger ribonucleic acid (mRNA) component, has been approved for emergency use.
In the statement made by the CSPC Pharmaceutical Group, headquartered in Hibey province, the vaccine called “SYS6006”, Chinese It has been announced that the National Medical Products Administration has given approval.
In the statement, “SYS6006”, the first mRNA type approved for emergency use in China, was found in clinical trials with the Omicron variant BA.5, BF.7, BQ.1.1., XBB.1.5 and CH.1.1. It has been reported to be effective against sub-variants.
In clinical trials conducted on 4 thousand people between December 10, 2022 and January 18, 2023, when Covid-19 cases were common in the country, it was determined that 85.5 percent protection was provided against the virus in people who were administered two doses.
8 currently developed by inactive, protein subunit and virus vector methods in mainland China. medicine Covid-19 vaccine is used.
Biontech and Moderna’s widely used mRNA type vaccines are administered in Hong Kong and Macau Special Administrative Regions.
Previously, 7 mRNA vaccine candidates were approved for clinical trials in the country, some of which were already being tested on humans.
After the abrupt lifting of the epidemic control measures that China has implemented since the beginning of the Covid-19 epidemic, called “zero cases”, requiring massive shutdown, quarantine and travel restrictions, on December 7, 2022, cases have increased rapidly, and the country has experienced the largest mass spread ever seen. had faced.
While it was estimated that at least 1 billion of the 1.4 billion population were infected with the virus in the intervening period, the Chinese administration declared that a “decisive victory” had been won against the Covid-19 epidemic on February 17.
[ad_2]
Source link
